Marc Schindewolf

Prof. Dr. Marc Schindewolf

orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2017 in JACC
Verified
Journal Article
Closed access
MSMarc Schindewolf
Marc Schindewolf
JSJulia Steindl
Julia Steindl
JBJan Beyer-Westendorf
Jan Beyer-Westendorf
SSSebastian Schellong
Sebastian Schellong
PDPascal Maria Dohmen
Pascal Maria Dohmen
ELEdelgard Lindhoff-Last
Edelgard Lindhoff-Last

4 July 2021 in Cells
Verified
Journal Article
Open access
PDF file
MTManovriti Thakur
Manovriti Thakur
BEBryce Evans
Bryce Evans
MSMarc Schindewolf
Marc Schindewolf
IBIris Baumgartner
Iris Baumgartner
YDYvonne Döring
Yvonne Döring
Neutrophil extracellular traps (NETs) are web-like structures of decondensed extracellular chromatin fibers and neutrophil granule proteins released by neutrophils. NETs participate in host immune defense by entrapping pathogens. They are pro-inflammatory in function, and they act as an initiator of vascular coagulopathies by providing a platform for the attachment of various coagulatory proteins. NETs are diverse in their ability to alter physiological and pathological processes including infection and inflammation. In this review, we will summarize recent findings on the role of NETs in bacterial/viral infections associated with vascular inflammation, thrombosis, atherosclerosis and autoimmune disorders. Understanding the complex role of NETs in bridging infection and chronic inflammation as well as discussing important questions related to their contribution to pathologies outlined above may pave the way for future research on therapeutic targeting of NETs applicable to specific infections and inflammatory disorders.

1 August 2022 in Journal of Vascular Surgery: Venous and Lymphatic Disorders
Verified
Journal Article
Closed access
UHUlrike Hügel
Ulrike Hügel
FKFarnaz Khatami
Farnaz Khatami
TMTaulant Muka
Taulant Muka
DKDavid Koeckerling
David Koeckerling
MSMarc Schindewolf
Marc Schindewolf
IBIris Baumgartner
Iris Baumgartner

23 April 2018 in Clinical & Experimental Allergy
Verified
Journal Article
Closed access
PDF file
MSMarc Schindewolf
Marc Schindewolf
MPM. Paulik
M. Paulik
HKH. Kroll
H. Kroll
RKR. Kaufmann
R. Kaufmann
MWM. Wolter
M. Wolter
Ralf J. LudwigRalf J. Ludwig
Ralf J. Ludwig

25 November 2024 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
RBRupert Bauersachs
Rupert Bauersachs
Edelgard Lindhoff-LastEdelgard Lindhoff-Last
Edelgard Lindhoff-Last
RKRobert Klamroth
Robert Klamroth
AKAndreas Koster
Andreas Koster
MSMarc Schindewolf
Marc Schindewolf
HMHarry N. Magnani
Harry N. Magnani
(1) Background: Danaparoid sodium is a heparinoid antithrombotic that has been used for over 40 years for prophylaxis of DVT in non-HIT patients and for the treatment of heparin-induced thrombocytopenia (HIT) with and without thrombosis. This update summarises current information on its pharmacology and reviews danaparoid dose management in a broad spectrum of clinical situations, including off-label indications. (2) Methods: Evidence from published clinical studies, case reports, compassionate use of danaparoid, and spontaneously reported serious adverse events is summarised and analysed by an interdisciplinary expert group to develop a consensus on dosing regimens of danaparoid for complex clinical situations, including vulnerable patient populations. (3) Results: Dosing regimens are proposed, together with monitoring recommendations and target anti-factor Xa ranges. (4) Conclusion: In a comprehensive summary detailed interdisciplinary dosing recommendations are described to provide a basis for safe and effective use of danaparoid.

14 March 2017 in Contact Dermatitis
Verified
Journal Article
Closed access
PDF file
MSMarc Schindewolf
Marc Schindewolf
ARAndreas Recke
Andreas Recke
DZDetlef Zillikens
Detlef Zillikens
ELEdelgard Lindhoff‐Last
Edelgard Lindhoff‐Last
Ralf J. LudwigRalf J. Ludwig
Ralf J. Ludwig